fda bpc-157 category 2 compounding This is the first vote from the FDA's Pharmacy Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the will make FDA's Overreach on Compounded Peptides
FDA's Overreach on Compounded Peptides A big shift in the peptide landscape!! It's being reported that many of the peptides previously restricted under FDA compounding guidance may soon be able to be legally compounded again through BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner
Pay in 4 interest-free payments of $7.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15

